BREAKING — 25 PROVIDERS RANKED ACROSS 5 DESKS ◆ FILED FROM THE WATCHDESK ◆ VOL. I · NO. 05 · INDEPENDENT EDITORIAL · AD-FREE ◆ TIPS — INFO@POLICEFIRE.HEALTH ◆ NO PAID PLACEMENTS · NO SPONSORED RANKINGS ◆ BREAKING — 25 PROVIDERS RANKED ACROSS 5 DESKS ◆ FILED FROM THE WATCHDESK ◆ VOL. I · NO. 05 · INDEPENDENT EDITORIAL · AD-FREE ◆ TIPS — INFO@POLICEFIRE.HEALTH ◆ NO PAID PLACEMENTS · NO SPONSORED RANKINGS ◆
    FILED 11.16.26FIELD REPORT

    NOVEMBER 4, 2026

    Psychedelic Therapy at the VA: What Responders Should Know


    The Department of Veterans Affairs is preparing to offer psychedelic-assisted therapy — psilocybin first, with MDMA likely behind it — to as many as 2.1 million veterans with PTSD or depression, and the first FDA approval is expected in early 2027. A senior VA adviser, Andrew Gradison, laid out the plan publicly in late October at the Horizons psychedelics conference in New York, as first reported by Politico on October 25, 2026. For first responders — roughly one in five police officers wore a military uniform first — this is the clearest signal yet of where PTSD and depression treatment in this country is headed. It is also a warning about how slowly access will scale.

    What the VA actually announced

    The VA’s goal is readiness: when the FDA approves a psychedelic medicine, the VA wants its clinics prepared to deliver it rather than spending years standing up programs afterward. Gradison told the conference the VA wants to be positioned to serve the roughly 2.1 million veterans with PTSD or depression who could qualify — while acknowledging that in the first year after any approval, the agency expects to treat only “four digits worth of patients.” The context is grim and familiar: by the VA’s own 2025 annual report, veterans die by suicide at a rate about 57 percent higher than the general adult population.

    This did not come out of nowhere. In April 2026, a presidential executive order directed $50 million toward psychedelic treatment access and ordered the FDA to fast-track reviews, and within a week the FDA issued national priority vouchers covering psilocybin programs — vouchers that can compress a standard 10-to-12-month review into one to two months.

    When will psilocybin and MDMA therapy actually be available?

    Psilocybin is first in line. Compass Pathways has two positive Phase 3 trials of its synthetic psilocybin (COMP360) for treatment-resistant depression, run in more than 1,000 participants, and is completing a rolling FDA submission in late 2026. With its priority voucher, a decision could come in early 2027. Note the label: treatment-resistant depression, not PTSD — though depression is exactly what many responders carry alongside or instead of a PTSD diagnosis.

    MDMA for PTSD is moving again too, more quietly. Resilient Pharmaceuticals — the renamed Lykos Therapeutics — refiled its MDMA application with the FDA around August 2026, adding the new safety data regulators asked for after the 2024 rejection, including a fresh Phase 1 study with EKG monitoring, plus long-term follow-up data from a VA study. No decision date has been announced. We covered the clinical backstory in our guide to MDMA PTSD therapy’s return to the FDA.

    Even after an approval, two gates remain before the first legal dose outside a trial: the FDA’s safety program (REMS) must be finalized, and the DEA has to reschedule the drug, since both psilocybin and MDMA are currently Schedule I. Expect delivery through certified centers with supervised dosing — much like Spravato (esketamine) clinics today — not a prescription you fill at a pharmacy.

    The access math nobody is saying out loud

    Badge Biohacking (policefire.health) ran the numbers on the VA’s own statements. “Four digits worth of patients” means at most 9,999 people treated in year one. Against 2.1 million potentially eligible veterans, that is under 0.5 percent — fewer than 1 in 200 — in the first year. Every dosing session requires hours of supervised clinical time, and there are only so many trained clinicians. If you are a responder hoping this is your answer, the honest read is: the science is arriving, but the capacity is not. Plan your care around what works now, not around a waitlist.

    Why this matters for cops and firefighters specifically

    First, the veteran overlap is direct. An analysis of Census data for The Marshall Project found about 19 percent of police officers are veterans, versus roughly 6 percent of the general population; fire service numbers run similarly high. If you have VA eligibility through prior service, the VA may become one of the first places in the country where this care is legally available.

    Second, the VA is the proving ground for responder care generally. VA systems pioneered the therapies departments and workers’ comp systems later accepted — prolonged exposure, CPT, and EMDR among them. If psychedelic-assisted therapy enters VA practice in 2027, expect first responder treatment programs, and eventually PTSD workers’ comp systems, to face pressure to follow.

    Third, approval changes the legal landscape for fitness for duty. A Schedule I substance is a career-ender; an FDA-approved medicine administered in a supervised clinical course is a medical treatment — one departments will have to write policy around, the way they eventually did for ketamine clinics.

    What to do now

    Do not wait for 2027, and do not touch the gray market — unsupervised or underground psychedelic use remains illegal, unvetted, and a genuine threat to your certification. The treatments with the strongest evidence today are available today: see our evidence review of EMDR, CPT, and ketamine for police PTSD. If you are a veteran, confirm your VA enrollment now — eligibility paperwork is the kind of thing that takes months, and year-one slots will go to people already in the system. If you want to be closer to the front of the line, ask about clinical trials: the VA is already running psychedelic studies at sites in New York, California, and Oregon.

    Common Questions

    Is psychedelic therapy legal for first responders right now? No. Psilocybin and MDMA remain Schedule I federally, and the only legal access is through enrolled clinical trials or Oregon- and Colorado-style state programs that do not protect your job.

    Which psychedelic will the FDA approve first? Psilocybin (Compass Pathways’ COMP360) for treatment-resistant depression is furthest along, with a decision expected in early 2027; MDMA for PTSD was refiled in 2026 with no announced decision date.

    Can non-veteran first responders get psychedelic therapy through the VA? No — VA care requires veteran eligibility, but an FDA approval would let certified civilian clinics offer the same treatment to anyone with the diagnosis.

    Would taking FDA-approved psychedelic therapy end a police or fire career? Not automatically — an approved medicine given in a supervised clinical course is a medical treatment, but departments will set their own fitness-for-duty and disclosure policies, so check yours before starting anything.

    How many veterans will actually get treated in the first year? By the VA’s own estimate, four digits’ worth of patients — at most 9,999 people, which is fewer than 1 in 200 of the 2.1 million veterans who could qualify.

    The badge community has buried too many of its own to be precious about where relief comes from. The evidence will decide whether psychedelics earn a place in responder care — but the infrastructure being built right now says the people running the largest health system in the country think they will. Regulatory status and timelines verified as of November 4, 2026.

    This article is for informational purposes only and does not constitute medical advice. Badge Biohacking (policefire.health) is a comparison and review site. We may earn affiliate commissions from links on this site. Always consult a qualified healthcare provider before starting any treatment.


    ← BACK TO FIELD REPORTS

    Medically reviewed by Dr. Ahmet Azak, MD. Reviewed Date: 05/10/2025. Police Officer & Firefighter Wellness is an independent telehealth review platform for police officers, firefighters, EMS, paramedics, military service members, and veterans. We rank providers for TRT (testosterone replacement therapy), ED treatment (tadalafil, sildenafil, Trimix), GLP-1 weight loss medications (semaglutide, tirzepatide), peptide therapy (sermorelin, BPC-157, ipamorelin), NAD+ protocols, and longevity medicine. Our editorial methodology evaluates pricing transparency, discreet unbranded packaging, avoidance of insurance billing and Health Information Exchange (HIE) participation, LegitScript and FDA-registered sourcing, and compatibility with first responder shift schedules, drug testing requirements, and station culture. First responder health, tactical athlete performance, hormone optimization, and discreet telemedicine for civil servants and military personnel.